MARKET

SLXN

SLXN

Silexion Therapeutics Corp
NASDAQ
0.5298
+0.2608
+96.95%
After Hours: 0.4800 -0.0498 -9.40% 19:59 05/20 EDT
OPEN
0.6299
PREV CLOSE
0.2690
HIGH
0.6660
LOW
0.3658
VOLUME
327.99M
TURNOVER
--
52 WEEK HIGH
22.36
52 WEEK LOW
0.2310
MARKET CAP
2.22M
P/E (TTM)
-0.0561
1D
5D
1M
3M
1Y
5Y
1D
Nasdaq Gains 100 Points; Target Earnings Top Views
Benzinga · 12h ago
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 14h ago
Silexion Therapeutics Posts Wider Q1 Loss, Advances SIL204 Into Phase 2/3 Trials; Stock Up
NASDAQ · 16h ago
Silexion Therapeutics GAAP EPS of -$0.85 beats by $0.44
Seeking Alpha · 2d ago
*Silexion Therapeutics 1Q Research and Development Approximately $1.4M >SLXN
Dow Jones · 2d ago
*Silexion Therapeutics 1Q EPS 85c >SLXN
Dow Jones · 2d ago
Weekly Report: what happened at SLXN last week (0511-0515)?
Weekly Report · 2d ago
Silexion Therapeutics Q1 EPS $(0.85) Beats $(1.29) Estimate
Benzinga · 5d ago
More
About SLXN
Silexion Therapeutics Corp is an Israel-based oncology-focused biotechnology company. The Company is engaged in development of treatments for unsatisfactorily treated solid tumor cancers, which have the mutated KRAS oncogene. The KRAS gene is an oncogene that is involved in regulation of cell division as a result of its ability to relay external signals to the cell nucleus. Based on its research of refractory solid tumor cancers, it is developing a platform focused on the silencing of the KRAS oncogene using ribonucleic acid (RNA)-interference therapeutics. Its lead product candidate, SIL-204B, consists of locally administered small interfering RNAs (siRNA), in an extended-release formulation, as a preferred treatment of locally advanced pancreatic cancer patients, in combination with standard-of-care chemotherapy. Its clinical-stage pipeline is focused on treatment for pancreatic cancer (PC) tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected.

Webull offers Silexion Therapeutics Corp stock information, including NASDAQ: SLXN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLXN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SLXN stock methods without spending real money on the virtual paper trading platform.